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Chlamydia trachomatis is a bacterial infection spread through sexual contact, including oral, anal 
and vaginal sex.  This largely asymptomatic infection is highly prevalent in the United States and 
has been for the past 40 years: indeed, chlamydia is the most common sexually transmitted 
disease (STD) in the United States.  Left untreated, chlamydia can cause Pelvic Inflammatory 
Disease (PID), ectopic pregnancy, and infertility in women; complications are rare in men.  
Screening for this infection is necessary for its control and prevention and is a matter of great 
importance to public health.  Currently, the Centers for Disease Control and Prevention (CDC) 
recommend annual chlamydia screening for all sexually active women aged 25 years and 
younger, older women with risk factors (new sex partners or multiple sex partners), and all 
sexually active men who have sex with men (MSM).  This thesis examines the history of the 
CDC’s chlamydia screening recommendations, the implications of the CDC’s recommendation 
that all sexually active young women be screened for the infection, and the barriers to following 
current chlamydia screening recommendations.  Through a close analysis of available evidence, 
this thesis asserts that the CDC’s chlamydia screening recommendations are inconsistent, have 
not been updated to align with current diagnostic testing developments, place the burden of the 
disease upon women, further stigmatize people who are marginalized, and most importantly, fail 
to include sexually active heterosexual young men, a population that transmits the infection to 
women.  New chlamydia screening recommendations are necessary based on the lack of control 
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over disease prevalence, the unequal burden of the disease on women, and the increased 
feasibility of diagnostic measures for men.  Consequently, the CDC’s guidelines should be 
updated.  The guidelines should continue to recommend the annual screening of all sexually 
active women aged 25 and under and also recommend the annual screening of all sexually active 
young men aged 25 and under, as well as men and women over the age of 25 with risk factors. 
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1.0  INTRODUCTION 
Chlamydia trachomatis is a bacterial infection spread through sexual contact, including oral, anal 
and vaginal sex (Centers for Disease Control and Prevention, 2010b).  This largely asymptomatic 
infection is highly prevalent in the United States and has been for the past 40 years: indeed, 
chlamydia is the most common sexually transmitted disease (STD) in the United States.  In 2009, 
over 1.2 million cases of chlamydia were reported to the Centers for Disease Control and 
Prevention (CDC), and research suggests that annually an estimated two million cases remain 
undiagnosed or unreported (Groseclose, Zaidi, Delisle, Levine, & St Louis, 1999). Left 
untreated, the infection can cause Pelvic Inflammatory Disease (PID), ectopic pregnancy, and 
infertility in women; complications are rare in men.  
Chlamydia is often referred to as a “silent epidemic” due to the asymptomatic nature of 
the infection (Walsh, Anderson, & Irwin, 2000).  Genital chlamydia has also been described as a 
persistent pathogen due to the infection’s ability to persist for months without symptoms and 
cause continuing damage without coming to the attention of the patient (Stamm, 2001).  
Furthermore, this infection is not only hidden in the body but is also socially veiled.  Eng and 
Butler, editors of the Institute of Medicine’s report, The Hidden Epidemic: Confronting Sexually 
Transmitted Disease, state: 
STDs are difficult public health problems because of the “hidden” nature of these 
diseases.  The sociocultural taboos related to sexuality are a barrier to STD 
prevention efforts on a number of levels.  Effective STD prevention efforts also 
are hampered by biological characteristics of STDs, societal problems, 
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unbalanced mass media messages, lack of awareness, fragmentation of STD-
related services, inadequate training of health care professionals, inadequate 
health insurance coverage and access to services, and insufficient investment in 
STD prevention. (Eng & Butler, 1997, p. 2) 
 
Since the 1980s, guidelines have been in place to promote chlamydia screening.  Several 
organizations have recommendations for chlamydia screening, including the U.S. Preventive 
Services Task Force, the American Medical Association, the American College of Obstetricians 
and Gynecologists, and the American Academy of Pediatrics.  The CDC’s screening 
recommendations are supported and informed by these organizations (Walsh, et al., 2000). 
Currently, the CDC (2010b) recommends that all sexually active women aged 25 years and 
younger, older women with risk factors (new sex partners or multiple sex partners), and all 
sexually active men who have sex with men (MSM) be screened annually for chlamydia.  
Despite established screening recommendations and effective treatment guidelines, the 
prevalence of chlamydial infections has remained extremely high and has actually increased in 
recent years (Centers for Disease Control and Prevention, 2010a).   
The purpose of this thesis is to describe the history of the CDC’s chlamydia screening 
recommendations, examine the implications of the CDC’s recommendation that all sexually 
active young women be screened for the infection, examine adherence to current chlamydia 
screening recommendations, and subsequently propose new national screening 
recommendations.  The specific questions that are considered in this thesis are: 1) How have 
chlamydia screening recommendations and guidelines changed since they were first introduced 
by the CDC in 1985?  2) Why are there no recommendations to screen all sexually active young 
men aged 25 years and younger?  3) What are the social consequences and implications of 
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primarily screening women for chlamydia?   4) What are the barriers to following the CDC’s 
screening recommendations?  
Reviews of scientific and professional literature are central to this thesis.  PubMed and 
the CDC’s website were searched for relevant articles.  The key phrases for the search included 
“chlamydia screening,” “chlamydia screening recommendations,” “chlamydia guidelines,” 
“chlamydia sequelae,” “chlamydia in men,” “chlamydia in MSM,” “chlamydia screening and 
social implications,”  “barriers to chlamydia screening,” and  “impact of chlamydia screening.”  
The organization of this thesis is to first present what is reliably studied and known about 
chlamydia screening measures.  Next, the discussion and recommendations section integrates 
and analyzes all relevant information that has been found regarding the CDC’s screening 
recommendations.  The objective of this thesis is to present a position on the CDC’s screening 
recommendations and ultimately propose a new set of recommendations.   
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2.0  GENITAL CHLAMYDIAL INFECTIONS 
Genital chlamydia trachomatis is a bacterial infection that is spread through sexual contact in the 
form of vaginal, anal and oral sex.  Some researchers assert that 85% to 90% of chlamydial 
infections are asymptomatic (Peipert, 2003), while others estimate that 70% of women and 40% 
of men have no symptoms (Walsh, et al., 2000).  Additional studies have also estimated that 95% 
of infected men and 75% of infected women do not exhibit symptoms of chlamydial infection 
(Meyers, Halvorson, & Luckhaupt, 2007).  While it is not clear from the research exactly what 
percentages of women and men have no symptoms, it is evident that chlamydia is largely 
asymptomatic.  
The most common clinical manifestation of the infection in men is nongonoccal 
urethritis, which can cause symptoms such as urethral discharge and dysuria (painful urination) 
(Peipert, 2003).  The infection may also cause epididymitis, which causes intrascrotal 
inflammation (Krieger, 1984).  There are limited data about the effect of chlamydia on male 
fertility and complications are very rare in men (Paavonen & Eggert-Kruse, 1999).   
Unlike in men, chlamydia can produce serious complications in women.  The clinical 
manifestations in women depend on the site of the infection: infection of the urethra and lower 
genital tract can result in dysuria and abnormal vaginal discharge; symptoms of an infection in 
the upper genital tract include pelvic discomfort or pain and irregular uterine bleeding (Peipert, 
2003).  Left untreated, chlamydial infections can have severe sequelae.  Between 15% and 40% 
  5 
of women with untreated infections will develop Pelvic Inflammatory Disease (PID) (Walsh, et 
al., 2000).  PID can cause inflammation of the uterus, ovaries, and fallopian tubes, and the 
consequences can include infertility, chronic pelvic pain, and ectopic pregnancy (Haggerty, et 
al., 2010).  PID caused by chlamydia is one of the most preventable causes of infertility 
(Paavonen & Eggert-Kruse, 1999).  One episode of PID can cause around 10% to 12% of 
females to become infertile (Paavonen & Eggert-Kruse, 1999; Walsh, et al., 2000).  In addition, 
infection with chlamydia during pregnancy can lead to serious complications for the infant, as 
the infection can be transmitted during delivery.  Anywhere from 30% to 50% of infants born to 
infected mothers will have conjunctivitis and as many as 20% of infants will develop chlamydial 
pneumonia (Peipert, 2003; Walsh, et al., 2000).  Chlamydia can also induce preterm labor 
(Paavonen & Eggert-Kruse, 1999).  Finally, in both infected men and women, chlamydia 
increases the risk of infection with HIV/AIDS if exposed (Fleming & Wasserheit, 1999). 
2.1 TESTING FOR CHLAMYDIA 
There are a variety of methods to test both men and women for chlamydia.  Cell cultures, 
enzyme immunoassay tests, direct fluorescent antibody tests, and nucleic acid amplification tests 
(NAATs) are all tests approved by the Food and Drug Administration for the detection of 
chlamydia (Centers for Disease Control and Prevention, 2010b; Stamm, 2001).  The cell culture 
method of testing uses test specimens collected by swabs from a woman’s endocervix and a 
man’s urethra; these specimens are inserted into a cell and stained with a specific antibody to 
determine if chlamydial bacteria is present (Centers for Disease Control and Prevention, 1985).  
Cell culture was the first available chlamydia screening method.  It is expensive, time 
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consuming, and technically difficult to perform (Black, et al., 2002).  Developed during the mid 
1980s and early 1990s, enzyme immunoassay tests and direct fluorescent antibody tests are 
nonculture methods that similarly detect the infection by smearing specimens on glass slides and 
then staining them with antibodies that bind to chlamydia bacteria (Centers for Disease Control 
and Prevention, 2002a; Gaydos, Ferrero, & Papp, 2008; Stamm, 2001).  These testing methods 
also utilize specimens from the endocervix for women and the urethra for men.  However, both 
of these diagnostic measures are not as specific or sensitive as NAATs.  NAATs, a molecular test 
that detects chlamydia-specific DNA and RNA sequences, became a widely used diagnostic 
method in the early 2000s (Centers for Disease Control and Prevention, 2002a).  In addition to 
specimens from the endocervix and urethra, NAATs can also be performed on urine specimens 
(Stamm, 2001). 
2.2 DEMOGRAPHICS 
In the past 20 years there has been a large increase in the number of reported chlamydial 
infections, which reflects expanded screening, more effective diagnostic measures, and increased 
reporting of infections from states and health agencies to the CDC (Centers for Disease Control 
and Prevention, 2010a).  Since 1994 chlamydial infections have been the most common sexually 
transmitted infection in the nation and make up the largest proportion of STDs reported to the 
CDC (Centers for Disease Control and Prevention, 2010a).  In 2009, 1,244,180 cases of 
chlamydia were reported to the CDC from all 50 states as well as the District of Columbia, the 
largest number of any condition ever reported (Centers for Disease Control and Prevention, 
2010a).  The total number of cases of chlamydia reported to the CDC in 2009 increased close to 
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three percent over those reported in the previous year.  This increase is believed to be due to 
increased screening efforts as well as more sensitive and specific tests; however, it is possible 
that this rate truly reflects a rise in infections (Centers for Disease Control and Prevention, 
2010a). 
The rates of reported chlamydial infections vary by gender, age, and race and ethnicity.  
The rate of infection among females was 592.2 cases per 100,000 and among males was 219.3 
cases per 100,000; the higher rate in women is most likely the result of a greater number of 
women being screened (Centers for Disease Control and Prevention, 2010a).  In fact, the CDC 
estimates that the rates of infection in men and women are actually quite similar.  The highest 
age-specific rates of infection are in those aged 15 to 19 and those 20 to 24.  All racial and ethnic 
minorities have high rates of infection: those among blacks is over eight times higher than 
whites, and rates among Hispanics and American Indians/Alaska Natives are also substantially 
higher than whites (Centers for Disease Control and Prevention, 2010a).  The prevalence of 
chlamydia in MSM is monitored by the STD Surveillance Network (SSuN): 42 STD clinics in 12 
cities are part of this program (Centers for Disease Control and Prevention, 2010a).  In 2009, the 
median chlamydia prevalence in the MSM population was 11.2% (Centers for Disease Control 
and Prevention, 2010a).   
2.3 COST OF INFECTION 
As of the year 2000, the average cost per case of chlamydia was $20.00 for men and $244.00 for 
women (Chesson, Blandford, Gift, Tao, & Irwin, 2004).  These costs are based upon screening 
tests with positive results, diagnosis and treatment of acute chlamydial infections, and sequelae 
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caused by acute infections (Chesson, et al., 2004).  The significantly larger average cost per case 
for women is attributed to sequelae in women, which are far more severe (Chesson, et al., 2004).  
Overall, the annual costs associated with chlamydial infections in the United States are 
approximately two to three billion dollars (Chesson, et al., 2004; Groseclose, et al., 1999; Hu, 
Hook, & Goldie, 2004).  
In sum, though chlamydial infections are largely asymptomatic, they cause severe 
sequelae and are extremely prevalent and costly.  Consequently, screening for this infection is 
not only necessary for the prevention of the infection, but is also a matter of great importance to 
public health. 
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3.0  HISTORY OF CHLAMYDIA SCREENING GUIDELINES AND 
RECCOMMENDATIONS 
Research about the specific properties of chlamydia began in the 1960s and 1970s with the 
discovery and subsequent availability of chlamydia cell cultures (Centers for Disease Control 
and Prevention, 1985; Stamm, 2001).  The availability of these cultures enabled researchers to 
discover that chlamydia trachomatis was the causative agent of both nongonococcal urethritis 
and PID as well as several neonatal conditions (Centers for Disease Control and Prevention, 
1985; Stamm, 2001).  In addition, research conducted during the early 1980s revealed that 
chlamydia was the most prevalent sexually transmitted disease in the United States (Thompson 
& Washington, 1983).  
The following sections provide an overview of the CDC’s chlamydia screening 
guidelines and recommendations in the United States from 1985 to 2010, and current screening 
recommendations in other nations. 
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3.1 CHLAMYDIA TRACHOMATIS INFECTIONS POLICY GUIDELINES FOR 
PREVENTION AND CONTROL, 1985 
In 1985, as a result of the discoveries of both the high prevalence of chlamydia and the serious 
complications it causes, the CDC summoned a group of experts to meet with the staff of the 
CDC’s Division of Sexually Transmitted Diseases to discuss measures and strategies to reduce 
and control chlamydial infections (Centers for Disease Control and Prevention, 1985).  In August 
1985, the CDC established their first policy guidelines for the prevention and control of 
chlamydia.  The purpose of these guidelines was simply to provide a source of guidance for 
health care providers in the United States by highlighting the prevalence of the disease, the 
morbidity associated with it, and the treatments available for both chlamydia and the syndromes 
it caused (Centers for Disease Control and Prevention, 1985).  The document also outlined the 
populations most at risk for infection: sexually active women under 20 years of age, teenage 
males, and individuals with multiple sex partners.  Screening was suggested for pregnant women 
under the age of 20, married pregnant women with multiple sex partners, and unmarried pregnant 
women.  Sex partners of those infected with chlamydia were to be notified, tested and treated.  
The recommended treatment for the infection was 100 milligrams of Doxycycline orally two 
times a day for seven days or 500 milligrams of Tetracycline orally four times a day for seven 
days.  The guidelines did not specify which diagnostic tests, either culture or non-culture, should 
be used.  
 In addition, the CDC also established priorities for screening based on gender and sex 
practices.  The guidelines (1985) asserted that “the screening of asymptomatic, high-risk women 
should be accorded the highest priority…the screening of heterosexual men should have a higher 
priority than screening homosexual men” (p. 61s).  Though the guidelines (1985) did not 
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explicitly explain the reasoning behind this assertion, a previous section did state that “the 
prevalence of urethral chlamydia among homosexual men is approximately one-third the 
prevalence among heterosexual men” (p. 55s), indicating that heterosexual men required more 
screening.  However, the CDC also asserted that “no single individual characteristic or 
practice…is in itself a sufficient criterion to define which persons should be screened” (p. 61s), 
thus providing no definitive guidance on who should be tested for chlamydia.  Ultimately, the 
1985 CDC guidelines did not establish specific screening recommendations, citing that the lack 
of inexpensive and reliable diagnostic measures restricted efforts to combat the infection.  
3.2 1989 STD TREATMENT GUIDELINES 
The 1989 guidelines differed slightly from those offered in 1985.  The 1989 Sexually 
Transmitted Disease Treatment Guidelines advised prioritizing the testing of “high-risk pregnant 
women, adolescents, and women with multiple sexual partners” (p. 22).  This document 
expanded upon previous guidelines regarding pregnant women, adding that all pregnant women 
should be tested for chlamydia during their first prenatal visit and that high-risk women (those 
under 25, with a past history or presence of STDs, and/or with new or multiple sex partners) 
should also be tested during their third trimester.  Another addition was that people who were 
infected with gonorrhea should also be treated for chlamydia due to the probability of 
coinfection, even if diagnostic testing of chlamydia was not available (Centers for Disease 
Control and Prevention, 1989).  The 1989 guidelines made similar suggestions regarding sex 
partner notification but added that if testing was unavailable, those suspected of having an 
infection should be treated (Centers for Disease Control and Prevention, 1989).  Notably, unlike 
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the previous guidelines, there was no mention of screening priorities regarding heterosexual and 
homosexual men. 
Overall, the recommended treatment for the infection remained the same in the updated 
guidelines.  And, once again, the CDC did not specify which diagnostic method—culture or non-
culture—should be used.  Like the 1985 guidelines, the 1989 guidelines provided only advice 
and did not establish specific recommendations. 
3.3 RECOMMENDATIONS FOR THE PREVENTIONS AND MANAGEMENT OF 
CHLAMYDIA TRACHOMATIS INFECTIONS, 1993 
The CDC report Recommendations for the Prevention and Management of Chlamydia 
trachomatis infections, 1993, updated previous guidelines.  Like the 1985 guidelines, this 
document focused solely upon chlamydia.  This document established the first set of CDC 
chlamydia screening recommendations for the nation.  Newly available diagnostic tests, such as 
direct fluorescent antibody tests and enzyme immunoassay tests were more cost-effective and 
easier to use than those previously available.  These diagnostic measures enabled the CDC to 
recommend a more aggressive prevention strategy through widespread screening (Centers for 
Disease Control and Prevention, 1993).  Screening was now considered a central component of 
chlamydia prevention due to the asymptomatic nature of the infection, and thus the CDC 
recommended the annual screening of all sexually active women under the age of 20, women 
aged 20 to 24 with risk factors (multiple or new sex partners during the last three months or 
inconsistent use of barrier contraception), and women over 24 years of age with multiple risk 
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factors (multiple or new sex partners during the last three months and inconsistent use of barrier 
contraception)  (Centers for Disease Control and Prevention, 1993).   
Unlike the 1989 guidelines, these recommendations did not advise screening pregnant 
women during the first trimester as this provided a long period of time for women to become 
infected; instead, the guidelines asserted that pregnant women should be screened only during 
the third trimester.  Also, treating people infected with gonorrhea for chlamydia regardless of 
diagnosis was discouraged, reflecting the expansion and ability of providers to diagnose patients 
with the infection.  In addition, the guidelines called for providers to notify their patients infected 
with chlamydia that their sex partners needed to be examined and treated and, when possible, for 
health care providers to offer treatment to the sex partners of those infected or refer them to other 
appropriate resources.  
The report also suggested the preferred sites for collecting screening specimens in women 
and men: the endocervix in women and the urethra in men.  According to the report (1993), 
screening tests for men “would be more acceptable if urine rather than intraurethral swab 
specimens could be used” (p. 24); however, insufficient evidence existed to recommend the use 
of urine for diagnosis.  With regard to treatment, one single dose of one gram of Azithromycin 
was found to effectively treat chlamydia and recommended treatment regimens include 100 
milligrams of Doxycycline orally two times a day for seven days or one gram of Azithromycin 
orally (Centers for Disease Control and Prevention, 1993).  It is evident from the report that new 
technological and medical advances since the late 1980s enhanced screening and expedited the 
treatment of chlamydial infections, which enabled the CDC to provide concrete 
recommendations. 
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3.4 1998 GUIDELINES FOR TREATMENT OF STDS 
The CDC’s 1998 Guidelines for the Treatment of Sexually Transmitted Diseases expanded upon 
previous recommendations and recommended that all sexually active adolescent females as well 
as sexually active women aged 20 to 24 be screened.  All other guidelines were the same as those 
in 1993.   
3.5 STD TREATMENT GUIDELINES, 2002 
The 2002 CDC guidelines included several key updates.  These guidelines raised the ceiling age 
for screening sexually active young women from 24 to 25 years of age and added the 
recommendation that older women with any risk factors (new sex partners or multiple sex 
partners) be screened.  In addition, unlike the 1989 and 1998 guidelines, the 2002 guidelines 
recommended that all pregnant women be tested for chlamydia at their first prenatal visit, instead 
of during the third trimester, to potentially reduce the harmful risks of chlamydia on pregnancy.  
The report recommended that women under the age of 25 and women with risk factors be tested 
during the third trimester as well (Centers for Disease Control and Prevention, 2002b).  
This edition also included new recommendations to screen MSM,* which was considered 
a special population at greater risk for HIV and STDs due to unsafe sex practices.  The CDC 
noted that while the rates of HIV had decreased in the MSM population in the previous decade, 
                                                 
* This document used the identity-free term MSM to refer to men who have sex with men instead 
of the word homosexual, which implies a specific sexual identity.  In 1994 the term MSM was 
coined and has become widely used in public health (Young & Meyer, 2005). 
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preliminary data showed an increased rate of STDs in HIV-infected MSM as well as a possible 
increase in HIV and STD infection rates.  The CDC (2002) speculated that these data reflected 
an increase in unsafe sexual behavior due to a number of factors including “improved HIV/AIDS 
therapy on quality of life and survival, ‘safer sex burnout,’ and in some cities, adverse trends in 
substance abuse” (p. 7).  Consequently, the CDC recommended annual screening for urethral 
infection for sexually active MSM with oral-genital exposure, and screening for rectal infection 
for men who had receptive anal intercourse in the past year.  In addition, screening was 
suggested approximately every three to six months for MSM who had anonymous or multiple 
sex partners, or who used illicit drugs in conjunction with sexual activities or had partners who 
did so.  The CDC also recommended that this population be screened for HIV, syphilis, and 
gonorrhea.   
A new guideline was also created for women who had suffered from a previous 
chlamydial infection. Women with chlamydia were to be rescreened three to four months after 
treatment due to the high prevalence of chlamydia found in those previously infected.  The high 
rates of reinfection were believed to be a result of continued sexual activity with a partner not 
treated for chlamydia or participation in sexual activity in an area with a high prevalence of 
chlamydial infections (Centers for Disease Control and Prevention, 2002b).  All other 
recommendations were the same as those in 1998.   
3.6  STD TREATMENT GUIDELINES, 2006 
In 2006, the CDC once again recommended screening all sexually active women aged 25 and 
under.  The guidelines (2006) stated: “evidence is insufficient to recommend routine screening 
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for C. trachomatis in sexually active young men, based on feasibility, efficacy, and cost-
effectiveness.  However, screening of sexually active young men should be considered in clinical 
settings with a high prevalence of chlamydia” (p. 38).  The 2006 screening recommendations for 
pregnant women and MSM were exactly the same as those made in 2002.   
This edition provided updated information on diagnostic measures.  According to the 
guidelines, in addition to swab specimens from the vagina or endocervix in women and the 
urethra in men, urine specimens could be used to diagnose the infection in both men and women.  
It also stated that NAATs were the most sensitive diagnostic measure available (Centers for 
Disease Control and Prevention, 2006).  
3.7 STD TREATMENT GUIDELINES, 2010 
The most recent publication of guidelines for the treatment of STDs feature a new 
recommendation to re-test pregnant women who tested positive for chlamydia three to six 
months later (Centers for Disease Control and Prevention, 2010b).  The screening 
recommendation for the MSM population is the same except for the addition of declaring 
NAATs to be the preferred testing approach for men.  All other recommendations are essentially 
the same as in 2006.  However, more detail with regard to screening men was added: the CDC 
(2010b) asserts that there is a dearth of evidence to recommend the screening of men and that 
“targeted chlamydia screening in men should only be considered when resources permit and do 
not hinder chlamydia screening efforts in women” (p. 45).  This statement clearly demonstrates 
that the CDC’s priority remains focused on screening women. 
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3.8 SUMMARY OF SCREENING GUIDELINES AND RECOMMENDATIONS 
This section summarizes the most significant changes in the CDC’s chlamydia screening 
guidelines and recommendations.  Screening guidelines were similar in 1985 and 1989: sexually 
active young women and pregnant women were the highest screening priority, but no official 
recommendations were created.  In 1993, the advent of more cost-effective and sensitive tests 
enabled the CDC to establish specific recommendations.  The CDC recommended annual 
screening of all sexually active women under the age of 20, women aged 20 to 24 with risk 
factors (multiple or new sex partners during the last three months or inconsistent use of barrier 
contraception), and women over the age of 24 with multiple risk factors (multiple or new sex 
partners during the last three months and inconsistent use of barrier contraception).  In 1998, the 
CDC expanded screening recommendations to also include the annual screening of sexually 
active women aged 24 and younger.  These annual screening recommendations were further 
expanded in 2002 to include all sexually active women aged 25 and younger as well as older 
women with risk factors (new sex partners or multiple sex partners).  The shifts in age range for 
screening reflect epidemiological data regarding disease prevalence in age groups.  In addition, 
in 2002 the CDC recommended screening all sexually active MSM, the first screening 
recommendation for any population of men.  To date, MSM is the only population of men that 
the CDC recommends screening.  The 2006 guidelines cited a lack of evidence to recommend 
screening sexually active young men, while the 2010 guidelines further add that screening males 
should only occur if it does not impede screening women.  Finally, the 2010 guidelines advise 
that NAATs are the preferred diagnostic approach for men. 
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3.9 SCREENING PROGRAMS AND GUIDELINES IN OTHER NATIONS 
The United States is not the only nation with chlamydia screening recommendations.  Several 
other countries utilize chlamydia screening programs and guidelines, as chlamydia is one of the 
most prevalent curable sexually transmitted diseases in the entire world (World Health 
Organization, 2001).   
Sweden was the first nation to introduce a national chlamydia screening program.  In 
1982 Sweden implemented programs to conduct opportunistic screening of women aged 30 and 
younger getting abortions, contraception, or prenatal care as well as screening male sex partners 
of women infected with chlamydia (Low, 2007).  In 1988, the Swedish government enacted a 
law requiring physicians to provide testing and treatment of chlamydia free of charge, report all 
cases of the infection, and notify partners of infected individuals (Low, 2007).   
In the years following the implementation of these policies and the extensive screening of 
young women, the prevalence of chlamydial infections decreased by more than 60% (Sylvan & 
Christenson, 2008).  The success of Sweden’s screening program has been attributed to a strong 
medical infrastructure, a culture of open-mindedness toward sexual health, and the small size of 
the nation (Low, 2007).  Sweden’s screening program is largely considered to be highly 
effective, resulting in other nations following its example (Low, 2007).  Denmark, Norway, 
Finland, and Italy all utilize similar opportunistic screening programs in which women are 
screened when they receive health care unrelated to chlamydial infections (European Centre for 
Disease Prevention and Control, 2008; LaMontagne, Fenton, Randall, Anderson, & Carter, 2004; 
Low, 2007).   
However, since 1995, the prevalence of chlamydia has begun to increase in Sweden as 
well as in other Scandinavian countries (Sylvan & Christenson, 2008).  The improved sensitivity 
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of diagnostic measures may partially explain the increase in infection rates (Low, 2007).  In 
addition, Low (2007) and Sylvan and Christenson (2008) argue that the decrease in chlamydia 
rates during the late 1980s and early 1990s in Sweden should also be attributed to safer sex 
behaviors that were a result of HIV/AIDS education campaigns that took place during those 
years.  According to Sylvan and Christenson (2008), the trend of safer sex behaviors reversed 
“when the fear of HIV diminished once it became obvious that there was no spread of HIV in the 
general population, as had been confirmed by the vigorous testing in Sweden” (p. 362).  Yet 
another critical rationale for the increase in the prevalence of chlamydia is the minimal inclusion 
of men in screening programs (Low & Egger, 2002; Sylvan & Christenson, 2008).  In recent 
years, researchers throughout the world have begun to question the exclusion of men in 
screening recommendations (Fenton, 2000; Low, 2007; Tebb, et al., 2005; Voelker, 2010).  In 
fact, England implemented a National Chlamydia Screening Programme (NCSP) in 2002, but 
unlike other nations decided to offer opportunistic screening to both men and women under the 
age of 25 (LaMontagne, et al., 2004).  
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4.0  WHY NOT SCREEN MEN? 
Noticeably absent from the CDC’s chlamydia guidelines are screening recommendations for 
heterosexual men.  There are several reasons why the CDC did not establish screening 
recommendations for men, including the priority to screen women over men due to the severe 
consequences the infection has in women, the lack of sensitive and noninvasive diagnostic 
screening tests for men, and the fact that male screening has not been found to be cost-effective 
in comparison to female screening.  The following section provides the rationale behind the 
CDC’s decision to exclude men from screening recommendations.  
Since 1985, women have been the primary targets for screening activities and 
recommendations as a result of the serious complications chlamydia causes in women.  From 
1988 to 1993 the CDC (2010a) initiated a chlamydia screening demonstration project in Health 
and Human Services Region X (Alaska, Idaho, Oregon, and Washington), providing chlamydia 
screening for women attending family clinics and STD clinics.  In one year, the prevalence of 
chlamydial infections in female patients served by these clinics declined by 65% (Walsh, et al., 
2000).  This demonstration project revealed that screening programs targeted at women lowered 
prevalence rates, and consequently led to the creation of other federally funded screening 
programs for women in several regions of the United States (Walsh, et al., 2000).  The success of 
the demonstration project led to a large number of studies being conducted regarding the cost-
effectiveness and benefits of screening young women for chlamydia.  Many studies, utilizing 
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sophisticated methods such as decision-analysis models and computer-based mathematical 
models, found that screening sexually active women was cost-effective, based upon the cost of 
screening in relation to the cost of treating complications associated with the infection (Estany, 
Todd, Vasquez, & McLaren, 1989; Howell, Quinn, & Gaydos, 1998; Hu, et al., 2004).  In 
addition, the wide availability of nonculture diagnostic tests, which were easier to use than cell 
culture tests, enabled the CDC (1993) to establish its first screening recommendations for 
women.  According to the CDC (1993), the “use of nonculture tests is a cornerstone of 
chlamydia prevention strategies” (p. 9).  Moreover, a study conducted by Scholes et al. in 1996 
determined that screening young women for chlamydia and subsequently treating those infected, 
dramatically reduced the incidence of Pelvic Inflammatory Disease, a serious complication of 
chlamydia (Scholes, et al., 1996).  Thus, it was evident that screening women for chlamydia was 
an effectual means of reducing infection prevalence as well as complications associated with the 
infection.  Correspondingly, the CDC was able to recommend the screening of young women 
based upon available evidence. 
However, while research found that screening women effectively reduced the prevalence 
of chlamydial infections, studies did not support the inclusion of men in screening efforts.*  
Literature from the late 1980s and early 1990s cited limited resources and the lack of effective 
diagnostic procedures for men as factors that inhibited the widespread screening of males for the 
infection (Genc, Ruusuvaara, & Mardh, 1993; Handsfield, 1987; Randolph & Washington, 1990; 
Rietmeijer, Judson, Van Hensbroek, Ehret, & Douglas Jr., 1991).  A 1990 study of chlamydia in 
heterosexual men found that diagnostic techniques were neither specific nor sensitive enough, 
                                                 
* It should be noted that the CDC’s guidelines and recommendations do not cite any specific 
studies or reports to justify or explain the exclusion of men from screening recommendations 
until the 2010 guidelines.   
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and more specific and sensitive detection methods were needed in order to implement cost-
effective screening programs for men (Rietmeijer, et al., 1991).  The urethral swabbing required 
to test men for chlamydia was also considered to be a serious barrier to the widespread screening 
of men (Centers for Disease Control and Prevention, 1993).  Gift, Blake, Gaydos and Marrazzo 
(2008) conducted a literature review on the cost-effectiveness of screening males for chlamydial 
infections; the articles reviewed in the paper were published between 1990 and 2007, and the 
majority found that screening women was more cost-effective than screening men (Gift, Blake, 
Gaydos, & Marrazzo, 2008).  The CDC’s exclusion of men in screening recommendations 
seemed logical given the lack of research to support such efforts, especially in relation to the 
strong evidence of the effectiveness of screening women. 
 However, new diagnostic technology has made screening males much simpler and more 
feasible.  Evidence has shown that urine-based NAATs are specific and highly sensitive.  
Furthermore, the noninvasive nature of the test also makes possible the widespread testing of 
asymptomatic males (Gaydos, et al., 2008; Marrazzo, et al., 2007; Tebb, et al., 2005).  In fact, 
this sensitive, noninvasive method of testing men for chlamydia has led to an increase in male 
screening; the detection of the presence of the disease among the male population has also 
increased (Satterwhite, Joesoef, Datta, & Weinstock, 2008).  In 2005, the rate of chlamydial 
infection in men was 159.4 per 100,000 males, while in 2009 the rate was 219.3 per 100,000 
males, a 37.6% increase (Centers for Disease Control and Prevention, 2010a).  The CDC 
attributed this surge to the increased usage of NAATs.  It is clear that this effective and 
noninvasive testing measure has removed a large barrier to screening males for the infection and 
also provided a means to determine the prevalence of the infection in men.   
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In recent years experts have begun to reconsider the chlamydia control and prevention 
strategy of primarily screening women.  Tebb et al. (2005) argue that with the new data on the 
prevalence of chlamydia in young men, “and the ease of obtaining urine-based specimens, it is 
time to reassess the need for screening sexually active young men to complement ongoing 
screening efforts among young women; it is even conceivable that these efforts would be 
synergistic” (p. 1809).  Kevin Fenton, former Director of the HIV and Sexually Transmitted 
Infections Department in the United Kingdom’s Health Protection Agency and current Director 
of the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, asserts 
that,  
although the benefits of screening asymptomatic women for C. trachomatis 
appear, on the surface, to outweigh those for asymptomatic men, this should not 
lead us to focus solely on women.  At best, chlamydia screening for women is 
concerned with secondary prevention.  Primary prevention can be achieved only 
by reducing the prevalence of chlamydial infection in men. (Fenton, 2000, p. 88) 
 
In addition, Gift et al. argue that while many studies found male screening to be less cost-
effective than female screening, numerous studies regarding screening women did not assess the 
implications of the transmission of chlamydial infections from males to females (Gift, et al., 
2008).  
In March 2006 the CDC convened a meeting with consultants to review evidence and 
address the issue of male chlamydia screening.  The consultants included individuals from the 
CDC’s Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and 
TB Prevention, the National Center for Chronic Disease and Public Health Promotion, and the 
Division of Reproductive Health.  This consultation also included experts from several 
universities, public health agencies, the U.S. Preventive Services Task Force, the American 
Medical Association, and several other organizations (Centers for Disease Control and 
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Prevention, 2007).  The purpose of this meeting was to review available evidence and make 
recommendations to programs that were interested in or were already screening men, not to 
provide any formal recommendation about adopting or expanding male screening.  The CDC 
stated that it planned to address the issue of broader recommendations for male screening in the 
future.  The following list was created to assist programs on the male populations who should be 
screened for chlamydia.  The CDC consultation (2007) advised screening: males attending STD 
clinics; males attending Job Corps; males less than 30 years of age entering prison; males 
entering juvenile detention centers; males less than 30 years of age in the military; partners of 
infected males; and, to rescreen males with chlamydial infection three months after the initial 
infection.  The report (2007) also noted that “there was no consensus on the state of cost-
effectiveness literature because of differences among studies regarding methodology and a lack 
of empiric evidence of the impact of screening men on the prevalence in women” (p. 5).   
Ultimately, the conclusion of the Male Chlamydia Screening Consultation (2007) was that:  
screening men for Ct [chlamydia] infection presents challenges to programs 
including limited resources, lack of knowledge of high prevalence settings, and  
lack of information on the impact of screening men for Ct on rates and outcomes 
in women.  A premise of the consultation was that STD programs should screen 
women less than 26 years of age for chlamydia infection as a primary focus and 
that screening men for Ct should be considered as a secondary focus to prevent Ct 
infection and sequelae among women. (p. 5) 
 
It is evident that unlike female screening, there is a dearth of conclusive research about the 
effectiveness of male screening.  However, no recommendations for further research on male 
screening were made and, as shown in Section 3.8, screening recommendations for the general 
male population remained the same from 2006 to 2010.  In addition, the 2010 guidelines and 
recommendations cite the above consultation when stating that there is not sufficient evidence to 
include men in chlamydia screening recommendations (Centers for Disease Control and 
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Prevention, 2010b).  While the CDC provided guidance for programs that wanted to screen men, 
the organization remained firmly committed to prioritizing the screening of women. 
Unlike for heterosexual men, there are chlamydia screening recommendations for men 
who have sex with men.  According to the CDC (2002), MSM have a high risk for infection with 
HIV in addition to other STDs.  Research found that the MSM population practiced unsafe sex 
and had high rates of STDs, including chlamydia (Centers for Disease Control and Prevention, 
1999; Chen, et al., 2002; Ciemins, et al., 2000; Geisler, Whittington, Suchland, & Stamm, 2002).  
While the frequency of sexually transmitted diseases in the MSM population declined from the 
mid 1980s to the mid 1990s, it began to steadily increase after this period.   And as noted in 
Section 3.5, the CDC (2002) speculated that unsafe practices were increasing due to the changing 
views on HIV/AIDS as a result of new advances in treatment as well as a rise in substance abuse 
in the MSM population.  As a result of the population’s unsafe sexual practices and the high 
prevalence of chlamydia in the MSM population in the United States, the 2002 CDC guidelines 
recommended the annual screening of sexually active men who have sex with men (Centers for 
Disease Control and Prevention, 2002b, 2006, 2010b).  There is no information on or reference 
to the purpose of screening MSM in relation to preventing chlamydia infection and sequelae in 
women. 
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5.0  SOCIAL CONSEQUENCES OF PRIMARILY SCREENING WOMEN 
Discussing the screening of women for chlamydia, researcher J. Dennis Fortenberry stated: 
“there are some people who might argue that this is ongoing gender discrimination that still 
makes women bear a greater part of the burden of something that our entire society has to be 
interested in [for] our reproductive health” (as cited in Voelker, 2010, p. 824).  While the current 
screening guidelines may place a burden primarily upon women, it has social consequences for 
both women and men.*   
Screening women disadvantages them as their sexual behavior is scrutinized while men’s 
behavior is not (Duncan & Hart, 1999a).  This sexual scrutiny transforms women into the 
transmitters and contractors of the infection (Duncan & Hart, 1999a).  A qualitative study using 
semi-structured interviews conducted at a family clinic in Glasgow, Scotland, found that women 
felt stigmatized about having chlamydia and also felt a great deal of anxiety about notifying their 
partners (Duncan, Hart, Scoular, & Bigrigg, 2001).   Duncan and Hart (1999a) state:  
the stigmatised nature of “aberrant” sexual behavior which is implied by STIs 
imbues the act of screening with a meaning that displaces the cost-benefit health 
behaviour model of decision making about sexual health, where sexually active 
women are expected to attend for screening because they are “objectively” at risk. 
(p. 240) 
 
                                                 
* As stated in the previous section, the only men that the CDC recommends screening are those 
who have sex with men. No articles or research could be found regarding the social 
consequences screening causes within the MSM population. 
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Screening only women means that women are diagnosed as infected with chlamydia, must bear 
the responsibility of notifying their partner, and may be blamed for spreading the infection.  
Similarly, in a qualitative study conducted in Ireland, women worried about the stigma of being 
tested for chlamydia, fearing they would be considered “bad girls” if tested (Balfe, Brugha, 
O'Donovan, O'Connell, & Vaughan, 2010).  Screening women may make them feel judged, 
labeled promiscuous, or irresponsible.   
In a qualitative study conducted at a London sexual health clinic, Darroch, Meyers, and 
Cassell (2003) found that men and women had very different experiences about testing positive 
for chlamydia.  Women possess more awareness about chlamydial infections than men, and 
unlike men, express self-blame regarding the contraction of the infection (Darroch, Myers, & 
Cassell, 2003).  The authors suggest that this study illustrates the fact that women feel 
stigmatized, while men see themselves as blameless (Darroch, et al., 2003).  Other studies have 
shown that screening for chlamydia can cause a great deal of anxiety in the women being tested 
(Balfe, et al., 2010; Darroch, et al., 2003; Duncan, et al., 2001).  Sexuality and sexually 
transmitted diseases are complicated and sensitive issues, and focusing chlamydia screening on 
women can produce a negative impact on women both psychologically and socially. 
In their article, “Sexuality and Health: the hidden costs of screening for Chlamydia 
trachomatis,” Duncan and Hart assert that focusing screening on women decreases the 
responsibility men feel regarding sexual health issues (Duncan & Hart, 1999b).  The authors 
further assert that focusing screening mainly on women ignores the importance of addressing the 
sexual health needs of men (Duncan & Hart, 1999b).  
Men also lack knowledge regarding chlamydia.  A study conducted in Scotland found 
that male participants’ knowledge about chlamydial infections was less than that of their female 
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counterparts.  Specifically, men were not aware that the infection was often asymptomatic 
(Lorimer & Hart, 2010).  Another study found that male participants who had heard of 
chlamydia were not clear about the symptoms and consequences of the disease (Chaudhary, et 
al., 2008).  In fact, most participants felt that chlamydia was not a serious health issue.  One man 
stated, “it is treatable though, I mean, maybe that makes you more laissez faire about it.  You 
think it’s not, like, the end of the world.  You can go to your GP and get it sorted out, not like 
something that would last for life” (Chaudhary, et al., 2008, p. 467).  Similarly, Darroch et al. 
(2003) found that the majority of males in their study perceived the severity of the infection to be 
low: one male patient interviewed did not believe that chlamydia was at all serious and only 
sought out treatment six weeks after being informed he was infected.  The belief that chlamydia 
is not a health concern for men is quite problematic.  While it is true that chlamydia does not 
typically cause serious complications for men, it does for women.   It is also significant that most 
men are unaware of the impact the infection can have on their female partners’ reproductive 
health.   
In addition, sexual health policies and guidelines are geared toward the needs of women 
and ignore or exclude men (Sonfield, 2002).  And as a result, the sexual health and reproductive 
knowledge and needs of males have been overlooked (Armstrong, 2003; Sonfield, 2002).  One 
qualitative study found that men consider chlamydia to be a woman’s issue (Chaudhary, et al., 
2008).  There is also very little research on the perceptions of men regarding chlamydia 
screening and their sexual health needs (Chaudhary, et al., 2008).  According to Sonfield (2002), 
just like women, men need to be screened for STDs to protect themselves and their partners, but 
“service providers, policymakers and the general public have little awareness of the scope of 
men’s sexual and reproductive health needs…this lack of awareness and understanding has 
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helped to create other obstacles to meeting men’s needs and has limited efforts to effect change” 
(p. 10).  Ignoring men’s sexual health, especially regarding chlamydia, has adverse consequences 
for both men and women. 
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6.0  BARRIERS TO SCREENING 
Though the recommendation to primarily screen women leads to a variety of social 
consequences, barriers exist to actually following this established screening recommendation.  In 
fact, the CDC’s chlamydia screening recommendations are often not followed.  According to 
Heijne, Tao, Kent, and Low (2010), who conducted a longitudinal study of regular annual 
chlamydia testing of women enrolled in health plans in the United States, “at present, the low 
rates of regular annual chlamydia testing do not comply with national recommendations and 
would not be expected to have a major impact on the control of chlamydia transmission at the 
population level” (p. 249).  The sections below describe the factors that impede the screening of 
chlamydia in the United States. 
6.1 PROVIDER ADHERENCE TO SCREENING RECOMMENDATIONS 
Several studies have shown that provider adherence to the CDC screening guidelines is quite 
low.  Pelvic examinations and preventative services such as Pap tests and urinalysis provide 
ample opportunities for practitioners to test women for chlamydia (Hoover & Tao, 2008).  
However, according to a study that surveyed 1600 physicians in Pennsylvania, including 
internists, general practitioners, obstetricians/gynecologists, and pediatricians, only 32% of 
physicians who perform gynecologic examinations would test a sexually active, asymptomatic 
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adolescent for the infection (Cook, et al., 2001).  A statewide survey of primary care providers in 
Colorado determined that roughly 54% of providers routinely screened female teenagers who 
were sexually active (Torkko, Gershman, Crane, Hamman, & Baron, 2000).  Another study of 
primary care providers in Washington and Idaho found that 42% of providers followed screening 
guidelines (McClure, et al., 2006).  In addition, an analysis of data from the 2005 National 
Ambulatory Medical Care Survey, a component of the National Health Care Survey 
administered by the CDC’s National Center for Health Statistics, found that of the 3.8 million 
visits made by women aged 15 to 25 to obstetrician/gynecologists in which pelvic examinations 
occurred, only 600 thousand patients were tested for chlamydia (Hoover & Tao, 2008).  
Adherence to the screening recommendations for MSM has also been found to be low (Kent, et 
al., 2005).  It is possible that some MSM do not inform their providers about their sexual 
practices and, consequently, their providers are not aware that these patients should be screened 
for chlamydia.  Although the CDC chlamydia screening guidelines have been in place for many 
years, it is evident that the majority of providers are not following these recommendations.  
Providers’ knowledge, beliefs and attitudes regarding chlamydia largely determine their 
screening practices (Cook, et al., 2001; McClure, et al., 2006).  McClure et al. (2006) found that 
20% of primary care providers surveyed were not aware of screening guidelines and 
recommendations.  Some providers asserted that they were not comfortable recommending 
screening to their patients (McClure, et al., 2006), while others reported that they simply did not 
believe that their patients were at risk for infection with chlamydia (Cook, et al., 2001; Torkko, 
et al., 2000).  Thus, a strong association was found between provider confidence and comfort 
with discussing sexual issues and screening patients (Cook, et al., 2001; McClure, et al., 2006; 
Torkko, et al., 2000).  If providers are not aware of chlamydia screening guidelines, or the high 
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prevalence of chlamydia, or are uncomfortable discussing sexual issues with patients, it seems 
fairly certain that screening recommendations will not be followed, and patients will not receive 
the services deemed necessary for the prevention and management of chlamydial infections. 
Other research has shown that race and ethnicity play a role in providers’ screening 
practices, as providers are more likely to test minorities for chlamydia (Christiansen-Lindquist, 
Tao, Hoover, Frank, & Kent, 2009; Wiehe, Rosenman, Wang, & Fortenberry, 2010; Wiehe, 
Rosenman, Wang, Katz, & Fortenberry, 2011).  Wiehe et al. (2010) also found provider testing 
practices to be strongly influenced by racial and ethnic stereotypes.  As noted in Section 2.2, 
according to the CDC (2010a), the rates of chlamydial infection are much higher in minorities.  
However, these recent studies suggest that these higher rates may partly be a result of the greater 
number of minorities screened. 
Gender and age are other factors associated with providers’ chlamydia screening 
practices. Female physicians are more likely than male physicians to test their patients for 
chlamydia; empirically-based findings are unclear as to the reasons for this difference (Cook, et 
al., 2001; McClure, et al., 2006; Torkko, et al., 2000; Wiesenfeld, et al., 2005).  Thus, according 
to Cook et al. (2001), “the reason for this consistent pattern of gender-specific behavior is not 
clear, but being female may represent a marker of differences in attitudes, knowledge, or 
previous personal experiences with health care” (p. 207).  In general, female providers were 
found to have more favorable attitudes towards sexually transmitted diseases and be more 
comfortable talking to their female patients about sexual health issues; these factors could 
account for female providers’ adherence to screening recommendations (Wiesenfeld, et al., 
2005).  In addition to female physicians, younger providers are also more likely to screen their 
patients (Cook, et al., 2001; McClure, et al., 2006; Wiesenfeld, et al., 2005).  McClure et al. 
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(2006) posit that older practitioners may have had less instruction on screening practices than 
their younger colleagues.  It is also possible that older male physicians, unlike their younger 
counterparts, are not comfortable discussing sexual health with young female patients.   
6.2 PATIENTS 
Like providers, patients’ decision-making around chlamydia screening is directly related to their 
knowledge, beliefs and attitudes toward the disease.  Numerous studies have found that young 
adults, both male and female, do not perceive themselves to be at risk for chlamydia and thus do 
not seek out screening (Barth, Cook, Downs, Switzer, & Fischhoff, 2002; Ford, Jaccard, 
Millstein, Bardsley, & Miller, 2004; Kaiser Family Foundation, 2001).  Male and female patients 
also have difficulty discussing sexual health and STDs with their providers (American Social 
Health Association, 2005; Blake, Kearney, Oakes, Druker, & Bibace, 2003).  In addition, 
according to the American Social Health Association (2005), many male and female adolescents 
and young adults incorrectly assume that STD testing is a routine part of care and do not ask 
their provider if they are being screened.  The lack of communication between patients and 
providers is a serious barrier to screening.   
Studies have also found that young men and women experience fear and anxiety around 
STD testing.  Focus groups with young men and women in the Job Corps and Department of 
Youth Services in Massachusetts found that participants thought being screened and potentially 
diagnosed with chlamydia could negatively impact them, stating: “‘you feel like a low-life 
person’” and “‘a person might feel dirty’” as well as “‘your partner might not want to have sex 
with you’” (Blake, et al., 2003, p. 525).  These fears are cited as a deterrent to seeking out 
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screening.  Physical anxiety surrounding the test may also be a barrier; the test itself prevented 
males from being tested, as urethral swabs are viewed as painful and uncomfortable (Blake, et 
al., 2003; Marrazzo, et al., 2007).  However, this barrier has been recently overcome with the 
introduction of noninvasive urine-based testing.   
6.3 HEALTH INSURANCE 
Insurance coverage is another factor that plays a role in chlamydia screening.  One study found 
that having health insurance coverage significantly lowers a person’s risk of chlamydial infection 
(Geisler, Chyu, Kusunoki, Upchurch, & Hook III, 2006).  Geisler et al. (2006) assert that there is 
“a significantly lower risk of chlamydial infection among insured individuals with these 
associations persisting even after controlling for race/ethnicity and age” (p. 394).  According to 
the National Center for Health Statistics, roughly 30% of young adults aged 20 to 29 lacked 
health insurance in 2008 (Cohen & Bloom, 2010).  Many millions of Americans in the age group 
in which chlamydia is most prevalent do not have any insurance coverage and are thus at an 
increased risk for infection and potential sequelae.   
According to data from the National Longitudinal Study of Adolescent Health, 
participants who did not have insurance or had Health Maintenance Organization (HMO) 
coverage were significantly less likely to report testing or treatment of sexually transmitted 
diseases in the previous year than their counterparts with Medicaid (Fiscus, Ford, & Miller, 
2004).  Several other studies obtained similar findings regarding the relationship between the 
type of insurance coverage and chlamydia screening among young women: women with 
Medicaid or public health insurance are more likely to be screened than women with other forms 
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of insurance (Heijne, Tao, Kent, & Low, 2010; Wiehe, et al., 2010; Wiehe, et al., 2011).  These 
studies suggest that the type of insurance coverage a woman has influences screening practices.  
The higher rates of screening among women with public insurance may reflect providers’ belief 
that low-income women are more likely to be infected with chlamydia.   
In 2000, the CDC’s Division of STD Prevention worked with the National Committee for 
Quality Assurance (NCQA), a non-profit organization dedicated to improving health care and 
health plans, to add the annual chlamydia screening of sexually active young women aged 16 to 
25 years of age as a performance measure for Healthcare Effectiveness Data and Information Set 
(HEDIS) (Burstein, et al., 2005).  HEDIS is a tool used by the NCQA to measure the 
performance of managed care health plans’ quality of care and service; the majority of 
commercial health plans and Medicaid report health services data to the NCQA (Burstein, et al., 
2005).  Moreover, health plans alter their practices to enhance and increase their performance 
ratings (Burstein, et al., 2005).  The CDC analyzed HEDIS data from the years 2000 to 2007 and 
found that the annual screening rate of sexually active women aged 15 to 25 jumped from 25.3% 
in 2000 to 41.6% in 2007 (Centers for Disease Control and Prevention, 2009).  There has been a 
clear increase in screening rates for women who are insured.  It seems that the establishment of 
chlamydia screening as a quality performance measure for health plans has improved adherence 
to screening recommendations.  This HEDIS performance measure will most likely continue to 
contribute to an increase in chlamydia screening in sexually active young women as health plans 
strive to improve their performance ratings.  Yet while screening rates have significantly 
increased among at-risk individuals, as identified by the CDC, these statistics indicate that there 
are many individuals who are still not being screened. 
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7.0  DISCUSSION AND RECOMMENDATIONS 
Primary prevention of a disease is defined as taking action to prevent its initial development, 
while secondary prevention is defined as the early detection of a disease as a means to reduce 
complications and transmission of the disease to others (Gordis, 2009).  The goals of chlamydia 
screening recommendations are not only to reduce the severe consequences of the infection but 
also to prevent the infection from spreading to others in the population.  Chlamydia is not only 
the most common STD in the United States, but it is also the infectious disease most frequently 
reported in the country (Centers for Disease Control and Prevention, 2010b).  It is clear that 
chlamydial infections are neither being controlled nor prevented in the United States.  The 
CDC’s chlamydia screening recommendations are inconsistent, have not been updated to align 
with current diagnostic testing developments, unfairly place the burden of the disease upon 
women, and most critically, fail to include sexually active heterosexual young men in screening 
recommendations.  
 In 1985 the CDC published its first policy guidelines regarding chlamydia and asserted 
that screening young women should be prioritized.  The reasoning behind prioritizing the 
screening of females is quite clear and logical: the consequences of the infection are severe in 
women.  Since they were first introduced in 1993, the CDC’s formal chlamydia screening 
recommendations have not changed a great deal.  Studies during the late 1980s and 1990s 
determined that screening women was a central means of reducing chlamydia prevalence and the 
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rates of PID (Scholes, et al., 1996).  The damage caused by chlamydial infections warranted 
screening in young women even though diagnostic tests were expensive (Estany, et al., 1989).  
The only significant changes in screening recommendations for women was raising the age 
bracket for annual screening from 20 and under, to 24 in 1998, and then another change to 
include women 25 years of age in 2002.  These modifications were based on the current 
epidemiological data available regarding chlamydial prevalence by age (Centers for Disease 
Control and Prevention, 1993, 2002b).  In addition, screening all pregnant women has 
consistently remained an important recommendation due to the complications chlamydia can 
cause in infants; only slight changes to recommendations for screening pregnant women have 
occurred since 1993.  Overall, the rationale for screening recommendations for women is clear 
and consistent in the CDC guidelines.   
Unlike for women, the CDC’s guidelines and recommendations for male chlamydia 
screening are inconsistent and their rationale is unclear.  In 1985, the CDC asserted that 
screening heterosexual men was a higher priority than screening homosexual men.  The 
document did not explicitly state the reasoning for this guideline; however, a previous section in 
the publication cited that heterosexual men had much higher rates of chlamydial infections than 
homosexuals and presumably also infected women, who were the primary targets of screening 
(Centers for Disease Control and Prevention, 1985).  Prioritizing screening heterosexual men, a 
population with higher rates of infection and one that transmits this infection to women, seemed 
completely logical.  The priority of screening heterosexual males over homosexuals was not 
referred to in 1989, 1993, or 1998.  It is unclear why screening priorities regarding heterosexual 
and homosexual men were not referenced or updated in subsequent years.  It is possible that 
screening priorities for these men were not referenced because the CDC decided to focus 
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screening priorities on women due to evidence that screening only women lowered disease 
prevalence.  
One rationale against screening men was due to the available diagnostic measures.  
Testing methods available during the 1980s, 1990s and early 2000s were not sensitive and 
required uncomfortable intraurethral swabs.  In fact, the 1993 recommendations and guidelines 
cited the diagnostic measure of intraurethral swabbing for men as a serious barrier to screening 
asymptomatic men for the infection and that urine specimens would make screening much more 
acceptable.  In the 2006 guidelines, the CDC stated that urine-based NAATs were the most 
sensitive tests available and in the 2010 guidelines declared this test to be the preferred 
diagnostic method.  Thus, one of the largest barriers to male screening, urethral swabs, is no 
longer an issue.  While NAATs are the CDC’s preferred method and are widely available for 
chlamydia testing, these changes have not led to any shift in recommendations for male 
screening.  Still, the availability of an effective testing approach did lead to an increase in interest 
regarding male screening. 
Greater interest in screening among men led the CDC to convene a consultation in 2006 
with researchers from the CDC and other medical organizations and universities.  The purpose of 
this Male Chlamydia Screening Consultation (2007) was to offer guidance to programs that are 
interested in or currently screen men.  The CDC understood that STD clinics and providers were 
interested in male screening and in need of assistance regarding screening parameters.  While the 
CDC was willing to provide guidance for programs, it was unwilling to change its overall 
recommendations.  Although the organization stated that it would continue to consider the 
important issue of male screening, the CDC did not modify its recommendations for men in the 
four years between the 2006 consultation and the publication of the most recent chlamydia 
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screening recommendations in 2010.  The 2010 guidelines cite a lack of evidence regarding the 
feasibility, efficacy, and cost-effectiveness of male screening.  Yet several research studies have 
found that male screening is feasible as a result of urine-based testing, and potentially cost-
effective due to the high rates of infection (Gaydos, et al., 2008; Gift, et al., 2008; Tebb, et al., 
2005).  Also, the Male Chlamydia Screening Consultation (2007) did not suggest or encourage 
further research regarding male screening, in spite of the fact that it was clear that current 
screening recommendations were not effectively controlling or preventing the infection, as 
chlamydia remains the most common STD in the United States since 1994 (Centers for Disease 
Control and Prevention, 2010a).  It seems apparent that the CDC requires more definitive 
evidence regarding the effectiveness of male screening.  The CDC may also be hesitant to 
dramatically alter its recommendations while adherence to current established recommendations 
is still quite low.   
Although no recommendations are in place for the general male population, in 2002 the 
CDC recommended annual screening for sexually active men who have sex with men.  The CDC 
cited preliminary data indicating that this population was at high risk for HIV/AIDS and other 
STDs.  But according to the CDC Male Chlamydia Screening Consultation in 2006, male 
screening should be considered secondary to female screening and a means to prevent the 
infection and its complications.  It should be observed that if the purpose of screening men is to 
prevent chlamydial infection and its sequelae in women, then there is essentially no reason to 
screen MSM.  While the MSM population is clearly at risk for chlamydial infections and other 
STDs as a result of unsafe sex practices, it seems rather illogical to provide screening 
recommendations only for men who are the least likely to infect women.  The recommendation 
to screen only the males of the MSM population may further stigmatize this minority group and 
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does nothing to protect women.  Though this population does suffer from high rates of various 
STDs, specifically syphilis and HIV (Centers for Disease Control and Prevention, 2010a), 
screening MSM as opposed to all men seems contradictory and ineffectual. 
Furthermore, the recommendation to screen only women for chlamydia is, in effect, 
tantamount to gender discrimination.  This recommendation places the onus of responsibility for 
sexual health solely on women.  The qualitative studies referenced in Section 5 illuminate the 
way in which women are burdened as a result of chlamydia screening.  Women alone are 
screened and, as a result, they experience the shame and stigma associated both with the need for 
screening due to their sexual practices, and the risk of a possible diagnosis (Duncan & Hart, 
1999b).  This recommendation essentially deems women to be the sole transmitters and carriers 
of the infection (Duncan & Hart, 1999a).  The view of women as responsible for STDs is not 
new.  According to medical historian Alan Brandt, campaigns to combat STDs during the early 
1900s essentially focused only upon eliminating prostitution (Brandt, 1987).  Brandt (1987) 
stated that “the campaign against the prostitute betrayed an underlying hostility towards 
women…social hygiene reformers and physicians assumed, in effect, that venereal infections 
could only be transmitted in one direction—that women bore the sole responsibility for the 
diseases” (p. 92).  It seems that current screening recommendations serve to further perpetuate a 
belief that has long been held in the United States.   
It is highly problematic as well as dangerous to have women solely bear the burden of 
chlamydia screening, as this infection is spread through sexual contact between both women and 
men.  Empirical findings on patient views of chlamydia screening reveal the way in which fear 
and shame surround screening and potential diagnosis with a sexually transmitted disease.  In 
addition, chlamydia has become an infection that is viewed as a “women’s issue.”  Women are 
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those who have more knowledge regarding this infection, as evidenced by several studies.  This 
increased knowledge is exhibited not only in female patients but in female health providers as 
well (Cook, et al., 2001).   Unlike their male counterparts, female providers appear to understand 
the need for screening, which is exhibited in their much higher rates of screening for chlamydial 
infections (McClure, et al., 2006; Torkko, et al., 2000).  As a result, both female patients and 
providers seem to bear the burden of responsibility for chlamydia screening.  
The CDC’s chlamydial infection screening recommendation also produces an unintended 
consequence: inadvertently discriminating against men.  Their burden is not stigma, fear, or 
shame, but ignorance.  The CDC’s endorsement of screening only women virtually ignores the 
sexual health conditions of heterosexual men.  While chlamydial infections in women are studied 
a great deal, there is barely any literature on chlamydia in heterosexual men (Chaudhary, et al., 
2008).   In fact, most studies on men’s perceptions regarding chlamydia screening come from 
England, a nation that recently implemented screening recommendations and programs for both 
men and women.   
Both screening recommendations and, ultimately, screening practices have further 
stigmatized people who are already marginalized.  Minority female patients are more likely to be 
screened than their majority counterparts as are women covered by Medicaid (Christiansen-
Lindquist, et al., 2009; Wiehe, et al., 2010).  Providers clearly assume that minorities and low-
income women practice unsafe sexual behaviors.  As mentioned earlier in Section 6.1, increased 
screening among these populations results both in greater detection of the infection and higher 
reported rates of infection.  As a consequence, this may present an inaccurate representation of 
disease prevalence; such a depiction of chlamydia prevalence leads again to stereotyping, 
perpetuating already held beliefs among some practitioners. 
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Many experts have questioned excluding men from screening recommendations in light 
of the array of recent findings regarding the infection (Fenton, 2000; Satterwhite, et al., 2008; 
Tebb, et al., 2005; Voelker, 2010).  Researcher J. Dennis Fortenberry states that it is necessary to 
challenge “our belief that just by screening young women we’re doing enough” (as cited in 
Voelker, 2010, p. 823).  Fortenberry is right.  Screening young women is clearly not enough, but 
this belief has become the established norm in the past 20 years, especially in the United States.  
This conviction is exemplified by the CDC’s decision to not update its screening 
recommendations even though chlamydia rates have remained extremely high and new 
technology has simplified male testing.   
New chlamydia screening recommendations are necessary based on the lack of control 
over disease prevalence, the unequal burden of the disease on women, and the increased 
feasibility of diagnostic measures for men.  The CDC guidelines should continue to recommend 
annual screening of all sexually active women aged 25 and under, but also recommend the 
routine screening of all sexually active young men aged 25 and under.  Screening is 
recommended for women over the age of 25 with risk factors (multiple or new sex partners) and 
new recommendations should also include men over the age of 25 with risk factors.  The 
recommendations to screen all pregnant women at the first prenatal visit and all sexually active 
MSM should remain the same.    
New screening recommendations alone cannot overcome all of the barriers that exist to 
chlamydia screening.  As noted earlier in Section 6, a variety of barriers to screening exist, from 
providers’ attitudes and knowledge to patients’ fears and insurance status.  Educating providers 
and patients about the importance of chlamydia screening is not a simple task, as it is both time-
consuming and expensive.  In addition, according to Hoover and Tao (2008), simply educating 
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providers is an insufficient method to increase screening rates.  But other methods do exist to 
increase the adherence to chlamydia screening recommendations.  Indeed, the inclusion of 
annual chlamydia screening for young women as a HEDIS performance measure for health plans 
increased the rates of screening a great deal from 2000 to 2007 (Burstein, et al., 2005; Centers 
for Disease Control and Prevention, 2009).  To ensure that providers and health plans would 
follow the new recommendations to screen sexually active young men aged 25 years and under, 
this recommendation must also become a performance measure for health plans. 
The CDC provides a section on clinical prevention guidance in Sexually Transmitted 
Diseases Treatment Guidelines, 2010.  The agency offers strategies to obtain patient sexual 
histories and techniques to encourage behaviors to reduce the risk of STDs in patients (Centers 
for Disease Control and Prevention, 2010b).  However, no guidelines are provided regarding 
techniques or measures to increase screening in clinical settings.  Guidance is needed to 
encourage and promote screening recommendations and should be included in the CDC’s 
treatment guidelines.  For instance, simple interventions can be used to promote and increase 
chlamydia screening, such as encouraging hospitals, clinics and private practices to place 
chlamydia collection swabs next to materials used to conduct Pap tests or bundling laboratory 
tests to include chlamydia screening when conducting urinanalysis (Burstein, et al., 2005; 
Hoover & Tao, 2008).  There are clearly a variety of strategies available that would undoubtedly 
increase adherence to chlamydia screening recommendations.  
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8.0  CONCLUSION 
Chlamydia is the most prevalent STD in the United States and is a serious public health issue.  
This highly prevalent and largely asymptomatic STD can cause severe health consequences in 
women.  As a result, screening recommendations are in place to combat chlamydial infections. 
This paper described the history of the CDC’s chlamydia screening guidelines and 
recommendations, examined the social consequences of primarily screening women for the 
infection, and presented barriers to current screening recommendations.  Analysis of this 
information found that screening recommendations are not consistent, place the burden of 
responsibility of the disease upon women, and further stigmatize minorities.  This analysis, in 
addition to findings regarding the feasibility of new diagnostic methods and the current lack of 
control over chlamydia prevalence, ultimately led to the assertion that the CDC’s current 
chlamydia screening recommendations need to be changed.  It is the position of this thesis that 
the CDC should recommend the annual screening of all sexually active women aged 25 and 
under, women over the age of 25 with risk factors (multiple or new sex partners), and also 
recommend the routine screening of all sexually active young men aged 25 and under, and men 
over the age of 25 with risk factors.  However, the recommendations to screen all pregnant 
women at the first prenatal visit and all sexually active MSM should remain the same. 
Several areas regarding chlamydia screening recommendations should be further 
researched.  There are very few studies about the knowledge and perceptions of heterosexual 
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men and MSM regarding chlamydia screening.  It would be beneficial to more fully understand 
the ways in which current recommendations impact both heterosexual men and MSM.  Further 
research should also be conducted regarding the relationship between the CDC’s chlamydia 
screening recommendations and practitioners’ practices, as this would illuminate the role of the 
CDC’s recommendations in actual practices and potentially address methods to increase 
adherence to chlamydia screening recommendations.  
It is evident that screening recommendations alone are insufficient to achieve control 
over this infection.  New screening recommendations coupled with simple interventions have the 
potential to control and prevent chlamydial infections in the United States.  In addition, including 
all sexually active young men in screening recommendations is not only a means to decrease the 
prevalence of the infection, but is also a way to equally distribute the responsibility of sexual 
health between the sexes.  Chlamydia is not a “women’s issue” or an infection present only in 
MSM.  Expanding screening recommendations to include sexually active heterosexual young 
men could be an important step to addressing men’s sexual health needs—needs that have been 
largely ignored.   
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